Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

The regulation of p53, p38 MAPK, JNK and XBP-1s by sphingosine kinases in human embryonic kidney cells.

Alsanafi M, Kelly SL, McNaughton M, Merrill AH Jr, Pyne NJ, Pyne S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Apr;1865(4):158631. doi: 10.1016/j.bbalip.2020.158631. Epub 2020 Jan 15.

PMID:
31954175
2.

WITHDRAWN: Ceramide and Sphingosine 1-Phosphate in adipose dysfunction.

Fang Z, Pyne S, Pyne NJ.

Prog Lipid Res. 2019 Aug 20:100991. doi: 10.1016/j.plipres.2019.100991. [Epub ahead of print] No abstract available.

PMID:
31442525
3.

Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P3.

Alganga H, Almabrouk TAM, Katwan OJ, Daly CJ, Pyne S, Pyne NJ, Kennedy S.

J Pharmacol Exp Ther. 2019 Oct;371(1):63-74. doi: 10.1124/jpet.119.257931. Epub 2019 Aug 1.

PMID:
31371480
4.

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases.

Omar F, Findlay JE, Carfray G, Allcock RW, Jiang Z, Moore C, Muir AL, Lannoy M, Fertig BA, Mai D, Day JP, Bolger G, Baillie GS, Schwiebert E, Klussmann E, Pyne NJ, Ong ACM, Bowers K, Adam JM, Adams DR, Houslay MD, Henderson DJP.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13320-13329. doi: 10.1073/pnas.1822113116. Epub 2019 Jun 17.

5.

Ceramide and sphingosine 1-phosphate in adipose dysfunction.

Fang Z, Pyne S, Pyne NJ.

Prog Lipid Res. 2019 Apr;74:145-159. doi: 10.1016/j.plipres.2019.04.001. Epub 2019 Apr 2. Review.

PMID:
30951736
6.

Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2.

Adams DR, Tawati S, Berretta G, Rivas PL, Baiget J, Jiang Z, Alsfouk A, Mackay SP, Pyne NJ, Pyne S.

J Med Chem. 2019 Apr 11;62(7):3658-3676. doi: 10.1021/acs.jmedchem.9b00162. Epub 2019 Mar 27.

PMID:
30889352
7.

Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse.

Greig FH, Nather K, Ballantyne MD, Kazi ZH, Alganga H, Ewart MA, Zaborska KE, Fertig B, Pyne NJ, Pyne S, Kennedy S.

Eur J Pharmacol. 2019 Jan 5;842:1-9. doi: 10.1016/j.ejphar.2018.10.027. Epub 2018 Oct 23.

8.

Does the Sphingosine 1-Phosphate Receptor-1 Provide a Better or Worse Prognostic Outcome for Breast Cancer Patients?

Pyne NJ, Pyne S.

Front Oncol. 2018 Sep 27;8:417. doi: 10.3389/fonc.2018.00417. eCollection 2018. No abstract available.

9.

Native and Polyubiquitinated Forms of Dihydroceramide Desaturase Are Differentially Linked to Human Embryonic Kidney Cell Survival.

Alsanafi M, Kelly SL, Jubair K, McNaughton M, Tate RJ, Merrill AH Jr, Pyne S, Pyne NJ.

Mol Cell Biol. 2018 Nov 13;38(23). pii: e00222-18. doi: 10.1128/MCB.00222-18. Print 2018 Dec 1.

10.
11.

Sphingosine Kinases as Druggable Targets.

Pyne S, Adams DR, Pyne NJ.

Handb Exp Pharmacol. 2018 Feb 20. doi: 10.1007/164_2018_96. [Epub ahead of print]

PMID:
29460151
12.

Cellular Signalling - Special issue to celebrate 75th birthday of Prof. Robert J. Lefkowitz.

Shukla AK, Pyne NJ.

Cell Signal. 2018 Jan;41:1. doi: 10.1016/j.cellsig.2017.10.015. Epub 2017 Oct 31. No abstract available.

13.

Sphingosine 1-phosphate and cancer.

Pyne NJ, El Buri A, Adams DR, Pyne S.

Adv Biol Regul. 2018 May;68:97-106. doi: 10.1016/j.jbior.2017.09.006. Epub 2017 Sep 15. Review.

14.

Sphingosine Kinase 1: A Potential Therapeutic Target in Pulmonary Arterial Hypertension?

Pyne NJ, Pyne S.

Trends Mol Med. 2017 Sep;23(9):786-798. doi: 10.1016/j.molmed.2017.07.001. Epub 2017 Aug 5. Review.

15.

Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors.

Pyne NJ, Adams DR, Pyne S.

Trends Pharmacol Sci. 2017 Jul;38(7):581-591. doi: 10.1016/j.tips.2017.04.003. Epub 2017 Jun 9. Review.

16.

Sphingosine kinase 2 and multiple myeloma.

Pyne NJ, Pyne S.

Oncotarget. 2017 Jul 4;8(27):43596-43597. doi: 10.18632/oncotarget.17420. No abstract available.

17.

Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells.

Pyne NJ, Pyne S.

Molecules. 2017 Feb 23;22(3). pii: E344. doi: 10.3390/molecules22030344. Review.

18.

Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis.

Barbour M, McNaughton M, Boomkamp SD, MacRitchie N, Jiang HR, Pyne NJ, Pyne S.

Br J Pharmacol. 2017 Jan;174(2):210-222. doi: 10.1111/bph.13670. Epub 2016 Dec 20.

19.

Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, Chiarini F, Barata JT, Pyne S, Pyne NJ, Martelli AM.

Leukemia. 2016 Nov;30(11):2142-2151. doi: 10.1038/leu.2016.208. Epub 2016 Jul 27. Review.

20.

Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension.

MacRitchie N, Volpert G, Al Washih M, Watson DG, Futerman AH, Kennedy S, Pyne S, Pyne NJ.

Cell Signal. 2016 Aug;28(8):946-55. doi: 10.1016/j.cellsig.2016.03.014. Epub 2016 Apr 6.

21.

Sphingosine Kinases: Emerging Structure-Function Insights.

Adams DR, Pyne S, Pyne NJ.

Trends Biochem Sci. 2016 May;41(5):395-409. doi: 10.1016/j.tibs.2016.02.007. Epub 2016 Mar 25. Review.

22.

Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.

Pyne S, Adams DR, Pyne NJ.

Prog Lipid Res. 2016 Apr;62:93-106. doi: 10.1016/j.plipres.2016.03.001. Epub 2016 Mar 10. Review.

24.

A reflection of the lasting contributions from Dr. Robert Bittman to sterol trafficking, sphingolipid and phospholipid research.

Pyne NJ, Tigyi GJ.

Prog Lipid Res. 2016 Jan;61:19-29. doi: 10.1016/j.plipres.2015.10.003. Epub 2015 Nov 14. Review.

25.

Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.

Pyne NJ, McNaughton M, Boomkamp S, MacRitchie N, Evangelisti C, Martelli AM, Jiang HR, Ubhi S, Pyne S.

Adv Biol Regul. 2016 Jan;60:151-159. doi: 10.1016/j.jbior.2015.09.001. Epub 2015 Sep 25. Review.

26.

Effect of ether glycerol lipids on interleukin-1β release and experimental autoimmune encephalomyelitis.

Boomkamp SD, Byun HS, Ubhi S, Jiang HR, Pyne S, Bittman R, Pyne NJ.

Chem Phys Lipids. 2016 Jan;194:2-11. doi: 10.1016/j.chemphyslip.2015.07.001. Epub 2015 Jul 14.

27.

Crystal Structure of Sphingosine Kinase 1 with PF-543.

Wang J, Knapp S, Pyne NJ, Pyne S, Elkins JM.

ACS Med Chem Lett. 2014 Oct 27;5(12):1329-33. doi: 10.1021/ml5004074. eCollection 2014 Dec 11.

28.

The life and work of Dr. Robert Bittman (1942-2014).

Pyne NJ, Kolesnick RN.

Biol Chem. 2015 Jun;396(6-7):827-30. doi: 10.1515/hsz-2014-0275. No abstract available.

29.

Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease.

Lim KG, Gray AI, Anthony NG, Mackay SP, Pyne S, Pyne NJ.

Arch Toxicol. 2014 Dec;88(12):2213-32. doi: 10.1007/s00204-014-1386-4. Epub 2014 Oct 25. Review.

30.

Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.

Evangelisti C, Evangelisti C, Teti G, Chiarini F, Falconi M, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Beak DJ, Bittman R, Pyne S, Pyne NJ, Martelli AM.

Oncotarget. 2014 Sep 15;5(17):7886-901.

31.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

34.

Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1.

Rutherford C, Childs S, Ohotski J, McGlynn L, Riddick M, MacFarlane S, Tasker D, Pyne S, Pyne NJ, Edwards J, Palmer TM.

Cell Death Dis. 2013 Nov 21;4:e927. doi: 10.1038/cddis.2013.455.

35.

Structure-activity relationships and molecular modeling of sphingosine kinase inhibitors.

Baek DJ, MacRitchie N, Anthony NG, Mackay SP, Pyne S, Pyne NJ, Bittman R.

J Med Chem. 2013 Nov 27;56(22):9310-27. doi: 10.1021/jm401399c. Epub 2013 Nov 14.

36.

The role of sphingosine 1-phosphate in inflammation and cancer.

Pyne NJ, Ohotski J, Bittman R, Pyne S.

Adv Biol Regul. 2014 Jan;54:121-9. doi: 10.1016/j.jbior.2013.08.005. Epub 2013 Sep 11. Review.

37.

Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis.

Pyne NJ, Pyne S.

Oncogene. 2014 Jun 26;33(26):3361-3. doi: 10.1038/onc.2013.292. Epub 2013 Jul 22.

38.

New perspectives on the role of sphingosine 1-phosphate in cancer.

Pyne S, Pyne NJ.

Handb Exp Pharmacol. 2013;(216):55-71. doi: 10.1007/978-3-7091-1511-4_3. Review.

PMID:
23563651
39.

Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors and activators.

Liu Z, MacRitchie N, Pyne S, Pyne NJ, Bittman R.

Bioorg Med Chem. 2013 May 1;21(9):2503-10. doi: 10.1016/j.bmc.2013.02.042. Epub 2013 Mar 7.

40.

Synthesis of selective inhibitors of sphingosine kinase 1.

Baek DJ, MacRitchie N, Pyne NJ, Pyne S, Bittman R.

Chem Commun (Camb). 2013 Mar 14;49(21):2136-8. doi: 10.1039/c3cc00181d. Epub 2013 Feb 7.

41.

Sphingosine 1-phosphate is a missing link between chronic inflammation and colon cancer.

Pyne NJ, Pyne S.

Cancer Cell. 2013 Jan 14;23(1):5-7. doi: 10.1016/j.ccr.2012.12.005.

42.

Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers.

Pyne S, Edwards J, Ohotski J, Pyne NJ.

Front Oncol. 2012 Dec 3;2:168. doi: 10.3389/fonc.2012.00168. eCollection 2012.

43.

The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells.

Watson DG, Tonelli F, Alossaimi M, Williamson L, Chan E, Gorshkova I, Berdyshev E, Bittman R, Pyne NJ, Pyne S.

Cell Signal. 2013 Apr;25(4):1011-7. doi: 10.1016/j.cellsig.2013.01.002. Epub 2013 Jan 11.

44.

The roles of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells.

Tonelli F, Alossaimi M, Natarajan V, Gorshkova I, Berdyshev E, Bittman R, Watson DG, Pyne S, Pyne NJ.

Biomolecules. 2013 Jun 10;3(2):316-33. doi: 10.3390/biom3020316.

45.

The p.Arg86Gln change in GARP2 (glutamic acid-rich protein-2) is a common West African-related polymorphism.

Gibriel AA, Tate RJ, Yu Y, Rawson-Lax E, Hammer HM, Tettey JN, Pyne NJ, Converse CA.

Gene. 2013 Feb 15;515(1):155-8. doi: 10.1016/j.gene.2012.11.005. Epub 2012 Nov 30.

PMID:
23201897
46.

The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.

Tonelli F, Alossaimi M, Williamson L, Tate RJ, Watson DG, Chan E, Bittman R, Pyne NJ, Pyne S.

Br J Pharmacol. 2013 Mar;168(6):1497-505. doi: 10.1111/bph.12035.

47.

Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis.

Pyne NJ, Dubois G, Pyne S.

Biochim Biophys Acta. 2013 Jan;1831(1):228-38. doi: 10.1016/j.bbalip.2012.07.003. Epub 2012 Jul 16. Review.

PMID:
22801038
48.

Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer.

Ohotski J, Edwards J, Elsberger B, Watson C, Orange C, Mallon E, Pyne S, Pyne NJ.

Int J Cancer. 2013 Feb 1;132(3):605-16. doi: 10.1002/ijc.27692. Epub 2012 Jul 11.

49.

Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b.

Lim KG, Tonelli F, Berdyshev E, Gorshkova I, Leclercq T, Pitson SM, Bittman R, Pyne S, Pyne NJ.

Int J Biochem Cell Biol. 2012 Sep;44(9):1457-64. doi: 10.1016/j.biocel.2012.05.012. Epub 2012 May 23.

PMID:
22634604
50.

Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer.

Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, Pyne S, Pyne NJ, Edwards J.

Br J Cancer. 2012 Apr 10;106(8):1453-9. doi: 10.1038/bjc.2012.98. Epub 2012 Mar 29. Erratum in: Br J Cancer. 2012 Aug 7;107(4):756.

Supplemental Content

Support Center